436 related articles for article (PubMed ID: 28004346)
21. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
Kaur P; Chaurasia CS; Davit BM; Conner DP
J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
[TBL] [Abstract][Full Text] [Related]
22. Dissolution testing for generic drugs: an FDA perspective.
Anand O; Yu LX; Conner DP; Davit BM
AAPS J; 2011 Sep; 13(3):328-35. PubMed ID: 21479700
[TBL] [Abstract][Full Text] [Related]
23. What makes a generic medication generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
[TBL] [Abstract][Full Text] [Related]
24. Particle Size Distribution Equivalency as Novel Predictors for Bioequivalence.
Ngeacharernkul P; Stamatis SD; Kirsch LE
AAPS PharmSciTech; 2018 Oct; 19(7):2787-2800. PubMed ID: 30117041
[TBL] [Abstract][Full Text] [Related]
25. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
26. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
27. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
Yomota C
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
[TBL] [Abstract][Full Text] [Related]
28. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
29. Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities.
Roost MS; Potthast H; Walther C; García-Arieta A; Abalos I; Agostinho Freitas Fernandes E; Mendes Lima Santos G; Rodríguez Martínez Z; Tam A; Rodrigues C; Gutierrez Triana DA; Guzmán Aurela E; Rodríguez Rodríguez N; Aeh Park S; Kim J; Kariv R; Divinsky M; Jones B; Kuribayashi R; Myoenzono A; Kasuga M; Van Oudtshoorn J; Chi JF; Hung WY; Hsu LF; Crane C; Jarman T; Braddy A
J Pharm Pharm Sci; 2021; 24():548-562. PubMed ID: 34706215
[TBL] [Abstract][Full Text] [Related]
30. Viewpoint: observations on scaled average bioequivalence.
Patterson SD; Jones B
Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
[TBL] [Abstract][Full Text] [Related]
31. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
Mayers I; Bhutani M
J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
[TBL] [Abstract][Full Text] [Related]
32. The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release products.
Kondra PM; Endrenyi L; Tothfalusi L
Clin Ther; 2011 Sep; 33(9):1214-9. PubMed ID: 21849209
[TBL] [Abstract][Full Text] [Related]
33. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
García-Arieta A
Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823
[TBL] [Abstract][Full Text] [Related]
34. FDA moves closer to new requirements for NTI drugs.
Traynor K
Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
[No Abstract] [Full Text] [Related]
35. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
37. Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.
Sferrazza G; Siviero PD; Nicotera G; Turella P; Serafino A; Blandizzi C; Pierimarchi P
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):1007-1019. PubMed ID: 28656793
[TBL] [Abstract][Full Text] [Related]
38. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
[TBL] [Abstract][Full Text] [Related]
39. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
Jiang W; Kim S; Zhang X; Lionberger RA; Davit BM; Conner DP; Yu LX
Int J Pharm; 2011 Oct; 418(2):151-60. PubMed ID: 21803144
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products.
Kaur P; Jiang X; Stier E
J Pharm Pharm Sci; 2017; 20(0):252-257. PubMed ID: 28810949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
